Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

This publication has 25 references indexed in Scilit:

• Lack of specific γ-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation
  Blood, 2009
• Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
  Blood, 2009
• Adoptive cell therapy for the treatment of patients with metastatic melanoma
  Current Opinion in Immunology, 2009
• Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma
  Clinical Cancer Research, 2009
• Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
  Journal of Clinical Oncology, 2008
• Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
  Nature Medicine, 2008
• Minimally Cultured Tumor-infiltrating Lymphocytes Display Optimal Characteristics for Adoptive Cell Therapy
  Journal of Immunotherapy, 2008
• Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
  New England Journal of Medicine, 2008
• LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.
  2007
• Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo
  Cancer Immunology, Immunotherapy, 2007